The KAT7 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the human KAT7 gene. This product offers a loss-of-function model for investigating KAT7-dependent mechanisms in a heterogeneous knockout background, avoiding clonal isolation biases. The polyclonal format ensures robust functional analysis suitable for pooled screening and broad examination of gene perturbation effects.
The host HeLa cell line is an immortalized aneuploid cell line derived from human cervical adenocarcinoma. HeLa cells are widely used in biomedical research due to their rapid growth, ease of genetic manipulation, and well-characterized genome. Their cervical cancer origin provides a pathophysiologically relevant context for studying oncogenic processes, particularly given the line??s dysregulated cell cycle and epigenetic landscape.
KAT7 (HBO1) acetylates histone H4 at lysines 5, 8, and 12, promoting open chromatin for DNA replication origin licensing and transcriptional activation. It interacts with CDT1 and the MCM2-7 helicase complex to facilitate origin firing and coactivates c-MYC/MAX target genes. Regulated by upstream kinases CDK1/Cyclin B and ATM/ATR, KAT7 assembles into complexes with JADE1/2/3, BRPF1/2/3, and ING4/5 that define substrate specificity and chromatin targeting. KAT7-mediated acetylation impacts replication origin activation and expression of proliferation-associated genes, integrating cell cycle and DNA damage signals to orchestrate chromatin remodeling, origin licensing, and oncogenic transcription.
In HeLa cells, KAT7 knockout enables dissection of its role in cancer-relevant processes including deregulated DNA replication, genomic instability, and c-MYC-driven transcription. The aneuploid and highly proliferative nature of HeLa makes this model particularly valuable for studying how KAT7-dependent histone H4 acetylation influences origin licensing under replicative stress and sustains malignant phenotypes. The polyclonal population also allows analysis of functional heterogeneity and gene dosage effects.
This knockout cell product supports various applications including epigenetic profiling via ChIP-qPCR, cell cycle analysis by flow cytometry, DNA replication dynamics using EdU incorporation, transcriptomics with RNA-seq, and functional assays like colony formation. The cells are suitable for CRISPR-based synthetic lethality screens, drug sensitivity testing, and mechanistic studies of chromatinopathies and neurodevelopmental disorders. For further information, please contact Ascent Research.
